MedPath

SUPARTZ Versus Placebo in Osteoarthritis of the Shoulder

Not Applicable
Completed
Conditions
Osteoarthritis of the Shoulder
Interventions
Device: SUPARTZ®
Device: Phosphate Buffered Saline
Registration Number
NCT00479687
Lead Sponsor
Bioventus LLC
Brief Summary

This clinical trial is to determine the safety and effectiveness of three injections of SUPARTZ (sodium hyaluronate) compared with phosphate buffered saline (PBS) for the treatment of glenohumeral osteoarthritis of the shoulder. The trial contains two phases. Phase I is 26 weeks, double blinded, and subjects are randomized to either SUPARTZ or PBS treatment. Phase II is 26 weeks (total 52 weeks) and open-label so all subjects will receive SUPARTZ injections only.

Detailed Description

Phase 3 Study: Multi-center, randomized, double blinded, two phase study to determine the safety and efficacy of 3 injections of SUPARTZ for Osteoarthritis of the Shoulder

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
300
Inclusion Criteria
  • Glenohumeral Osteoarthritis (OA) confirmed by radiograph
  • Limitation of shoulder motion in at least one direction
  • Retained active range of motion of at least 30% in all directions
Exclusion Criteria
  • Full thickness rotator cuff tear or rotator cuff tendinopathy
  • Frozen shoulder
  • Female who is pregnant or lactating

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
SupartzSUPARTZ®SUPARTZ® 3 injections over 2 weeks
Phosphate Buffered SalinePhosphate Buffered SalinePhosphate Buffered Saline 3 injections over 2 weeks
Primary Outcome Measures
NameTimeMethod
Visual Analogue Scale (VAS: 0-100) for Pain on MovementPh1: weeks 7 - 26

Visual Analogue Scale (VAS) for pain on (shoulder) movement with a range of 0 to100; where 0=No pain at all and 100=Pain as bad as it can be.

Q: How bad is the pain in your study shoulder with activity or movement? (For example, when putting on a coat, sleeping on your study shoulder side, combing your hair, reaching a high shelf, etc.)

Reported is a single Least square mean point estimate over the 7-26 week time interval using the assessments collected at weeks 7, 13, 20, and 26

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath